News

NICE said in draft guidance that the breast cancer drug pertuzumab could not be recommended to treat HER2-positive breast cancer due to uncertainties over its long-term health benefits.

New Mexico-based PaizaBio will provide these services to JHL through its Hangzhou, China-based strategic partner, Ausia BioTech. The agreement is the first between JHL Biotech, which has deep

The $280 million project adds two new buildings to the 89-acre Devens campus: a Biologics Development Building for designing processes for the early production of investigational medicines, and

MONALEESA-2 is a pivotal Phase III trial of LEE011 (ribociclib), a cyclin dependent kinase inhibitor (CDK4/6), in combination with letrozole, compared to letrozole alone in postmenopausal women who

Noyada is an oral liquid version of captopril used in the treatment of paediatric chronic heart failure. Cevidra Laboratories, a French-based pharmaceutical company which specialises in ATU programmes

The second part will see 48 additional heavily pre-treated patients with HER2-positive breast cancer enrolled into the SYD985.001 trial. This marks an important next step in the development

"Dosing the first patient in our Phase 3 program is an important milestone for RDD Pharma in the development of our lead product candidate," said Jason Laufer, CEO

The announcement is part of a 2016 multimillion-dollar capital investment in instrumentation, which comes in the wake of ABC’s acquisition by California-based EAG in July of last year.

The approval pertains to patients who have locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-based chemotherapy, or within 12 months of receiving either neoadjuvant